Impact of the mutation profile on thrombotic risk in cancer patients

Thrombotic complications of antineoplastic therapy in oncohematological patients

“…Although not so commonly used in hematological patients, different thrombotic complications associated with a great variety of antineoplastic agents have been reported in solid tumors such as tamoxifen, VEGF inhibitors, and cellular cycle inhibitors, among others 2 .…”

“…Clinical practice guidelines do not recommend thromboprophylaxis on a routine basis for all the cases. However, it can be considered in high-risk patients (e.g., Khorana scores ≥ 2) 2,38,39 . Although the use of the Khorana score presents a good performance on in cancer patients, in the hematological patients, it underestimates the risk 3,40 .…”

“…Thrombotic risk associated with cancer, in general, and oncohematological processes, in particular, is associated with specific factors linked to the tumor, the patient, and treatment 1,2 . The location of the primary tumor is an important factor in such a way that, for instance, pancreas, brain and GI tract tumors are associated with a high risk, while risk is lower breast and prostate tumors.…”

Complicaciones trombóticas de la terapia antineoplásica en pacientes oncohematológicos. Quimioterapia y tromboembolismo

“…Existe controversia sobre el papel de la tromboprofilaxis primaria en pacientes no hospitalizados con cáncer. Las guías clínicas más recientes no recomiendan realizar tromboprofilaxis de manera sistemática en todos los casos, si bien puede considerarse en aquellos sujetos con alto riesgo (por ejemplo score de Khorana ≥ 2) 2,38,39 . Si bien la utilidad de la escala Khorana es clara en paciente oncológico, en paciente hematológico infraestima el riesgo 3,40 .…”

“…relacionado con factores específicos del tumor, factores relacionados con el paciente y factores relacionados con el tratamiento 1,2 . La localización del tumor primario es un factor importante, ya que, por ejemplo, los tumores de páncreas, cerebro y gastrointestinales se asocian con alto riesgo, mientras que este es inferior en los de mama o próstata.…”